ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0915

Utilization of the Tablo Hemodialysis System's Data Platform: An Analysis of 100,000 Acute Dialysis Treatments

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Schumacher, Josh, Outset Medical, Inc., San Jose, California, United States
  • Lim, Brittany, Outset Medical, Inc., San Jose, California, United States
  • Aragon, Michael A., Outset Medical, Inc., San Jose, California, United States
Background

The Tablo® Hemodialysis System (Tablo) is an all in one, easy-to-learn device featuring integrated water purification, on demand dialysate production and two-way wireless data transmission capable of providing therapy up to 24 hours in a hospital setting.

Limited connectivity of traditional hemodialysis systems constrains the ability to drive improvement in quality and efficiency of dialysis care. Tablo’s cloud-based data platform expedites care delivery in real time and informs on dialysis program metrics to facilitate quality improvement.

The objective was to demonstrate Tablo’s automated wireless data capabilities through analysis of 100,000 Tablo acute treatments.

Methods

Tablo data were collected through real-time transmission via a cloud-based, HIPAA compliant platform. Analysis was performed by combining prescribed and achieved data on consecutive treatments. Treatments were divided into groups based on treatment time of less than 6 hours (conventional therapy) or greater than 6 hours (extended therapy).

Results

A total of 100,000 treatments between April 2020 and May 2021 were analyzed. Treatments ranged from 2-24 hours. Treatment time success, defined as achieved within 10% of prescribed time, was 90.7% across the population. The most common reason for early termination was “User ended” (8.6%), with 0.7% due to “Device Directed”.

Mean total number of alarms per treatment was 2.5 across the population with no difference in alarm frequency (0.7 alarms per hour) between treatment groups. The most frequent clinically significant alarms were high and low venous pressures. Mean time to alarm resolution was 14 seconds with shorter alarm resolution time demonstrated in the IHD group (13 vs 22 secs).

Conclusion

With high utilization across a wide range of treatment times in the acute setting, Tablo successfully achieved treatment goals. The few observed alarms were quickly resolved by clinical users. Tablo’s robust data reporting capability enables the identification of treatment trends that can be used to drive quality improvement.

Summary of Tablo Treatment Parameters
Treatment GroupTreatment ParametersClinically Significant Alarms
Treatments PerformedPrescribed time
(hours)
Actual Time (hours)Actual Fluid Removal (L)Alarms per treatment (mean)Time to Alarm Resolution (seconds)High Venous PressureLow Venous PressureAir Venous Bloodline
IHD
(≤6 hrs)
946033.4 ± 0.6
(2.0 – 6.0)
3.3 ± 0.71.7 ± 1.12.3 ± 5.512.8 ± 32.11.7 ± 5.10.6 ± 1.60.1 ± 1.0
Extended
(6< to ≤24 hrs)
539711.8 ± 3.4
(6.1 – 24.0)
9.7 ± 3.91.9 ± 1.76.7 ± 16.822.3 ± 55.95.0 ± 14.70.9 ± 2.60.1 ± 2.2
Overall:100,0003.8 ± 2.1
(2.0 – 24.0)
3.6 ± 1.81.7 ± 1.22.5 ± 6.714.2 ± 36.61.8 ± 5.90.6 ± 1.70.1 ± 1.1

Funding

  • Commercial Support